Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris

被引:61
|
作者
Zhanel, George [1 ]
Critchley, Ian [2 ,3 ]
Lin, Lynn-Yao [2 ]
Alvandi, Nancy [2 ]
机构
[1] Univ Manitoba, Dept Med Microbiol & Infect Dis, Winnipeg, MB, Canada
[2] Allergan Plc, Irvine, CA USA
[3] Spero Therapeut, Cambridge, MA USA
关键词
Propionibacterium acnes; acne vulgaris; antibiotics; doxycycline; microbiological profile; microbiome; minocycline; sarecycline; tetracycline; STAPHYLOCOCCUS-AUREUS; ORAL ANTIBIOTICS; RESISTANCE; DOXYCYCLINE; MICROBIOME; MINOCYCLINE; MANAGEMENT; EFFICACY; TET(M); GUIDE;
D O I
10.1128/AAC.01297-18
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Sarecycline is the first narrow-spectrum tetracycline-class antibiotic being developed for acne treatment. In addition to exhibiting activity against important skin/soft tissue pathogens, sarecycline exhibits targeted antibacterial activity against clinical isolates of Cutibacterium acnes. In the current study, sarecycline was 16- to 32-fold less active than broad-spectrum tetracyclines-such as minocycline and doxycycline-against aerobic Gram-negative bacilli associated with the normal human intestinal microbiome. Also, reduced activity against Escherichia coli was observed in vivo in a murine septicemia model, with the 50% protective doses, or the doses required to achieve 50% survival, being >40 mg/kg of body weight and 5.72 mg/kg for sarecycline and doxycycline, respectively. Sarecycline was also 4- to 8-fold less active than doxycycline against representative anaerobic bacteria that also comprise the normal human intestinal microbiome. Additionally, C. acnes strains displayed a low propensity for the development of resistance to sarecycline, with spontaneous mutation frequencies being 10(-10) at 4 to 8 times the MIC, similar to those for minocycline and vancomycin. When tested against Gram-positive pathogens with defined tetracycline resistance mechanisms, sarecycline was more active than tetracycline against tet(K) and tet(M) strains, with MICs ranging from 0.125 to 1.0 mu l/ml and 8 mu l/ml, respectively, compared with MICs of 16 to 64 mu l/ml and 64 mu l/ml for tetracycline, respectively. However, sarecycline activity against the tet(K) and tet(M) strains was decreased compared to that against the wild type, which demonstrated MICs ranging from 0.06 to 0.25 mu l/ml, though the decrease in the activity of sarecycline against the tet(K) and tet(M) strains was not as pronounced as that of tetracycline. These findings support sarecycline as a narrow-spectrum tetracycline-class antibiotic that is effective for the treatment of acne, and further investigation into the potential reduced effects on the gut microbiome compared with those of other agents is warranted.
引用
收藏
页数:15
相关论文
共 42 条
  • [41] A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris
    Tanghetti, Emil A.
    Kircik, Leon H.
    Green, Lawrence J.
    Guenin, Eric
    Harris, Susan
    Martin, Gina
    Pillai, Radhakrishnan
    JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (06) : 542 - 548
  • [42] A randomized controlled double-blinded split-face prospective clinical trial to assess the efficacy, safety, and tolerability of a novel 3-step routine compared to benzoyl peroxide for the treatment of mild to moderate acne vulgaris
    Gern, Alison
    Walter, Jessica
    Xu, Shuai
    Vakharia, Paras P.
    ARCHIVES OF DERMATOLOGICAL RESEARCH, 2024, 316 (06)